{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":null,"name":"RevSTAR-123","nct_id":"NCT05949125","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=revstar-123-nct05949125. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"RevSTAR-123","arms":[{"description":"Following lymphodepleting therapy (from Day -5 to Day -3), R-TM123 will be administered as continuous infusion from Cycle 1 Day 1 and then will continue for 20 days. Allo-RevCAR01-T will be administered on Day 1.\n\nAll participants who tolerate Cycle 1 of R-TM123 and Allo-RevCAR01-T without clear disease progression or safety or other contraindications after Cycle 1, will be considered for consolidation cycles of up to 12 consecutive days each of continuous IV infusion of R-TM123 until relapse, unacceptable toxicity, potentially curative treatment option (alloHSCT), consent withdrawal, or maximum one-year overall treatment time (whichever occurs first).","label":"Allo-RevCAR01-T-CD123 treatment","type":"EXPERIMENTAL"}],"collaborators":["Allucent (NL) BV"],"completion_date":{"date":"2028-01","type":"ESTIMATED"},"conditions":["Acute Myeloid Leukemia, in Relapse","Acute Myeloid Leukemia Refractory"],"enrollment":{"count":37,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Cyclophosphamide (Non-IMP, Lymphodepletion)","otherNames":[],"type":"OTHER"},{"name":"Fludarabine (Non-IMP, Lymphodepletion)","otherNames":[],"type":"OTHER"},{"name":"R-TM123","otherNames":["R-TM123 is one component of the Allo-RevCAR01-T-CD123 treatment"],"type":"DRUG"},{"name":"Allo-RevCAR01-T","otherNames":["Allo-RevCAR01-T is one component of the Allo-RevCAR01-T-CD123 treatment"],"type":"DRUG"}],"last_update":"2026-09-24","lead_sponsor":"AvenCell Europe GmbH","official_title":"Multicenter, Open-label, Phase 1 Study of Allo-RevCAR01-T-CD123 Consisting of Genetically Modified T Cells Carrying Reverse Chimeric Antigen Receptors (Allo RevCAR01 T) in Combination With CD123 Target Module (R-TM123) for the Treatment of Patients With Selected Hematologic Malignancies Positive for CD123","overall_status":"RECRUITING","phases":["PHASE1"],"primary_completion_date":{"date":"2027-05","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Safety and tolerability","timeFrame":"At the end of cycle 1 (in total 28 days, given no treatment interruptions)"}],"references":[],"start_date":{"date":"2024-01-03","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Phase 1 Study of Allo-RevCAR01-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies (1b Dose Expansion)","url":"https://clinicaltrials.gov/study/NCT05949125"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/revstar-123-nct05949125"}